ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.29
0.98%
US Tech 100
20,197.20
2.58%
S&P 500
5,929.04
2.53%
US Dollar vs CAD
1.38976
-0.34%
Bitcoin
74,911.77
-0.97%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Nanobiotix SA (NBTX) Share Price

Nanobiotix SA

Nanobiotix SA (NBTX)

NASDAQ
4.14
-0.222
(-5.09%)
Closed November 06 3:00PM
Delayed by 15 minutes
2.13
-2.01
(-48.55%)
After Hours: 6:27PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
2.13
Bid
2.15
Ask
6.10
Volume
18,423
4.07 Day's Range 4.4099
0.00 52 Week Range 0.00
Market Cap
100.394M
Previous Close
4.362
Open
4.40
Last Trade
2000
@
2.13
(formt)
Last Trade Time
Financial Volume
US$ 78,079
VWAP
4.2382
Average Volume (3m)
-
Shares Outstanding
47,133,328
Dividend Yield
-
PE Ratio
-4.59
Earnings Per Share (EPS)
-0.84
Revenue
36.21M
Net Profit
-39.7M

About Nanobiotix SA

Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying ... Nanobiotix SA is a clinical-stage biotechnology company that focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. It develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its lead product candidate is NBTXR3, a preclinical research program for cancer immunotherapies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.nanobiotix.com
Headquarters
Paris, Paris, Fra
Founded
-
Nanobiotix SA is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NBTX. The last closing price for Nanobiotix was US$4.36. Over the last year, Nanobiotix shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Nanobiotix currently has 47,133,328 shares outstanding. The market capitalization of Nanobiotix is US$205.60 million. Nanobiotix has a price to earnings ratio (PE ratio) of -4.59.

Ask ADVFN Intelligence (AI)

NBTX Latest News

More News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

October 31 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

October 11 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 18 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 18 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 04 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

September 03 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 08 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

July 09 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

June 12 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

June 11 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CONLGraniteShares ETF Trust GraniteShares
US$ 43.12
(61.62%)
25.09M
ARBBARB IOT Group Ltd
US$ 0.802709
(42.20%)
227.42M
ELWSEarlyworks Co Ltd
US$ 6.00
(41.18%)
6.04M
CTKBCytek Biosciences Inc
US$ 7.40
(36.03%)
4.19M
TMCITreace Medical Concepts Inc
US$ 7.78
(35.07%)
3.15M
BNOXBionomics Ltd
US$ 0.2839
(-42.41%)
17.56M
VSTEVast Renewable Ltd
US$ 3.09
(-42.35%)
2.65M
ZCARZoomcar Holdings Inc
US$ 7.6899
(-41.74%)
1.33M
ZVSAZyVersa Therapeutics Inc
US$ 1.5242
(-39.99%)
2.07M
TNGXTango Therapeutics Inc
US$ 3.22
(-37.84%)
14.86M
ELABElevai Labs Inc
US$ 0.0173
(-19.16%)
306.06M
NVDANVIDIA Corporation
US$ 145.61
(4.07%)
235M
ARBBARB IOT Group Ltd
US$ 0.802709
(42.20%)
227.42M
SQQQProShares UltraPro Short QQQ
US$ 6.6503
(-8.02%)
217.37M
DJTTrump Media and Technology Group Corporation
US$ 35.955
(5.94%)
169.76M

NBTX Discussion

View Posts
Monksdream Monksdream 7 months ago
NBTX 10Q due 4/3
👍️0
Monksdream Monksdream 7 months ago
NBTX under $10
👍️0
Monksdream Monksdream 1 year ago
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0
Monksdream Monksdream 1 year ago
July 10, 2023
4:21 am ET
*Nanobiotix shares are trading higher after the company entered into a license agreement with Janssen Pharmaceutical for global co-development and commercialization of NBTXR3.
Benzinga
2:19 am ET
*Nanobiotix Enters License Agreement With Janssen Pharmaceutical For Worldwide Co-Development And Commercialization Of Potential First-In-Class Radioenhancer NBTXR3
Benzinga
Nanobiotix SA NASDAQ: NBTX

GoSymbol lookup
Health Care : Biotechnology | Small Cap Value | Based in FranceCompany profile
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
This security is an American depositary receipt
ADR Fees
👍️0

Your Recent History

NASDAQ
NBTX
Nanobiotix
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved